Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 5/20 | 0.43 |
| ▸ | PYGM | P11217 | 5/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260142 | 0.80 | HTR1A (0.43) | CRBNCA9TRPV1 | |
| SCHEMBL2062606 | 0.79 | INSR (0.46) | CRBN | |
| SCHEMBL7791600 | 0.72 | CRBN (0.49) | CRBNDDB1IKZF3PYGLPYGM | |
| SCHEMBL3442063 | 0.71 | MTNR1A (0.46) | — | |
| SCHEMBL15956894 | 0.71 | PYGL (0.50) | CRBNDDB1PYGLPYGMRIPK1 | |
| SCHEMBL2062702 | 0.71 | CA9 (0.44) | CRBNDDB1IKZF3CA9PYGL | |
| SCHEMBL29754050 | 0.70 | CA9 (0.42) | CRBNCA9TRPV1 | |
| SCHEMBL15957097 | 0.70 | RIPK1 (0.51) | CRBNDDB1PYGLPYGMRIPK1 | |
| SCHEMBL25584389 | 0.70 | RIPK1 (0.51) | PYGLPYGMRIPK1 | |
| SCHEMBL8330863 | 0.70 | RIPK1 (0.45) | CRBNDDB1PYGLPYGMTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | CRBN 2150/4885DDB1 2982/4885IKZF3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.